CBM light up lives mid banner advert
Advertisement: CJBS mid banner
Advertisement – Charles Stanley mid banner
Mid banner advertisement: BDO
Advertisement: EY Mid banner
Advertisement: Mogrify mid banner
Advertisement: Simpsons Creative
Advertisement: RSM
Advertisement: Cambridge Network mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: Hewitsons mid banner
ARM Innovation Hub
Advertisement: Howard Group mid banner
Advertisement mid banner S-Tech 1
Barr Ellison Solicitors – commercial property
Advertisement: EBCam mid banner
9 February, 2006 - 17:33 By Staff Reporter

Acquisition will tip the balance sheet says Fulcrum

AIM-listed drug development and services company, Fulcrum Pharma has acquired a company specialising in clinical trials for drugs for a maximum of £1.6m.AIM-listed drug development and services company, Fulcrum Pharma has acquired a company specialising in clinical trials for drugs for a maximum of £1.6m.

The acquisition of West Sussex based Quadramed is based on net assets of £300k in a combination of shares, loan notes and cash. The deal’s terms include an initial payment of £1.1 million and a performance based earn-out.

Fulcrum Pharma, which is based in Hemel Hempstead, said the deal significantly strengthens its existing regulatory services capability, both by expanding capacity and by broadening the range of services into marketing authorisation submissions. Fulcrum said it would also broaden its customer base.

The Hertfordshire business said it would be looking to make further acquisitions in the space "where suitable opportunities arise."

Quadramed, which was founded in 1991, reported sales of £1.36m and pre-tax profits of £466k. Its clients include biotechnology and pharmaceutical companies in both Europe and the US.

Jon Court, chief executive of Fulcrum Pharma, said: "This earnings enhancing acquisition delivers a key strategic objective and strengthens a part of our business that we have identified as offering growth potential."

Add new comment

Newsletter Subscription

Stay informed of the latest news and features